Table 3.
Adverse events by maintenance treatment
| Baseline characteristics | Olaparib (N = 30) | Olaparib plus bevacizumab (N = 27) | Niraparib (N = 60) | ||
|---|---|---|---|---|---|
| First occurrence of adverse events time | |||||
| < 1 month | 12 (40.0%) | 7 (25.9%) | 23 (38.3%) | ||
| 1–3 months | 5 (16.7%) | 10 (37.0%) | 4 (6.7%) | ||
| 4–6 months | 2 (6.7%) | 0 (0.0%) | 0 (0.0%) | ||
| > 6 months | 1 (3.3%) | 2 (7.4%) | 0 (0.0%) | ||
| Adverse events of drug interruption or discontinuation (Include duplicates) | |||||
| Anemia | 10 (33.4%) | 13 (48.1%) | 9 (15.0%) | ||
| Neutropenia | 5 (16.7%) | 3 (11.1%) | 4 (6.7%) | ||
| Thrombocytopenia | 1 (3.3%) | 4 (14.8%) | 17 (28.3%) | ||
| Nausea | 1 (3.3%) | 2 (7.4%) | 2 (3.3%) | ||
| Fatigue | 3 (10.0%) | 1 (3.7%) | 2 (3.3%) | ||
| Other Adverse events | 3 (10.0%) | 1 (3.7%) | 6 (10.0%) | ||
| Number of drug interruptions | |||||
| 1 | 8 (26.7%) | 6 (22.2%) | 23 (38.3%) | ||
| 2 | 6 (20.0%) | 5 (18.5%) | 8 (13.3%) | ||
| 3 | 3 (10.0%) | 4 (14.8%) | 0 (0.0%) | ||
| ≧4 | 3 (10.0%) | 4 (14.8%) | 1 (1.7%) | ||
| Dosage reduction of maintenance treatment | |||||
| Absent | 16 (53.3%) | 13 (48.1%) | 32 (53.3%) | ||
| Present | 14 (46.7%) | 14 (51.9%) | 28 (46.7%) | ||